Intelligent Bio Solutions Inc. (NASDAQ: INBS) Stock Competitors & Peer Comparison
See INBS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INBS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INBS | $2.51 | -5.28% | 1.6M | -0.28 | -$9.02 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $629.27 | +0.27% | 233.8B | 27.16 | $23.16 | +0.29% |
| DHR | $218.85 | +1.36% | 153.9B | 27.43 | $7.98 | +0.66% |
| NTRA | $332.03 | +2.21% | 47.6B | -251.54 | -$1.32 | N/A |
| A | $159.00 | +1.73% | 44.9B | 27.36 | $5.81 | +0.63% |
| IDXX | $556.93 | +2.03% | 43.9B | 39.17 | $14.22 | N/A |
| IQV | $259.82 | +1.47% | 42.8B | 21.43 | $12.13 | N/A |
| ILMN | $219.40 | +2.89% | 33.2B | 43.62 | $5.03 | N/A |
| WAT | $410.70 | +1.49% | 30.7B | 30.03 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
INBS vs DHR-PB Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, INBS's ROE is -1.70%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, INBS is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for INBS.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
INBS vs TMO Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, TMO has a market cap of 233.8B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while TMO trades at $629.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas TMO's P/E ratio is 27.16. In terms of profitability, INBS's ROE is -1.70%, compared to TMO's ROE of +0.13%. Regarding short-term risk, INBS is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for INBS.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
INBS vs DHR Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, DHR has a market cap of 153.9B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while DHR trades at $218.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas DHR's P/E ratio is 27.43. In terms of profitability, INBS's ROE is -1.70%, compared to DHR's ROE of +0.08%. Regarding short-term risk, INBS is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for INBS.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
INBS vs NTRA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NTRA has a market cap of 47.6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NTRA trades at $332.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NTRA's P/E ratio is -251.54. In terms of profitability, INBS's ROE is -1.70%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, INBS is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for INBS.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
INBS vs A Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, A has a market cap of 44.9B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while A trades at $159.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas A's P/E ratio is 27.36. In terms of profitability, INBS's ROE is -1.70%, compared to A's ROE of +0.21%. Regarding short-term risk, INBS is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for INBS.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
INBS vs IDXX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, IDXX has a market cap of 43.9B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while IDXX trades at $556.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas IDXX's P/E ratio is 39.17. In terms of profitability, INBS's ROE is -1.70%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, INBS is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for INBS.Check IDXX's competition here
IQVIA Holdings Inc. (NYSE: IQV)
INBS vs IQV Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, IQV has a market cap of 42.8B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while IQV trades at $259.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas IQV's P/E ratio is 21.43. In terms of profitability, INBS's ROE is -1.70%, compared to IQV's ROE of +0.22%. Regarding short-term risk, INBS is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for INBS.Check IQV's competition here
Illumina, Inc. (NASDAQ: ILMN)
INBS vs ILMN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ILMN has a market cap of 33.2B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ILMN trades at $219.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ILMN's P/E ratio is 43.62. In terms of profitability, INBS's ROE is -1.70%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, INBS is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for INBS.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
INBS vs WAT Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, WAT has a market cap of 30.7B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while WAT trades at $410.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas WAT's P/E ratio is 30.03. In terms of profitability, INBS's ROE is -1.70%, compared to WAT's ROE of +0.02%. Regarding short-term risk, INBS is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for INBS.Check WAT's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
INBS vs MTD Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MTD has a market cap of 28.2B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MTD trades at $1,395.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MTD's P/E ratio is 32.06. In terms of profitability, INBS's ROE is -1.70%, compared to MTD's ROE of -12.00%. Regarding short-term risk, INBS is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
INBS vs LH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, LH has a market cap of 27.6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while LH trades at $336.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas LH's P/E ratio is 19.95. In terms of profitability, INBS's ROE is -1.70%, compared to LH's ROE of +0.12%. Regarding short-term risk, INBS is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
INBS vs DGX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, DGX has a market cap of 27B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while DGX trades at $244.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas DGX's P/E ratio is 24.10. In terms of profitability, INBS's ROE is -1.70%, compared to DGX's ROE of +0.14%. Regarding short-term risk, INBS is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for INBS.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
INBS vs GH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, GH has a market cap of 22.9B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while GH trades at $170.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas GH's P/E ratio is -48.91. In terms of profitability, INBS's ROE is -1.70%, compared to GH's ROE of +2.11%. Regarding short-term risk, INBS is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
INBS vs EXAS Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas EXAS's P/E ratio is -95.37. In terms of profitability, INBS's ROE is -1.70%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, INBS is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for INBS.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
INBS vs MEDP Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MEDP trades at $620.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MEDP's P/E ratio is 36.39. In terms of profitability, INBS's ROE is -1.70%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, INBS is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
INBS vs ILMNV Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ILMNV's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to ILMNV's ROE of N/A. Regarding short-term risk, INBS is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for INBS.Check ILMNV's competition here
PerkinElmer, Inc. (NYSE: PKI)
INBS vs PKI Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PKI's P/E ratio is 41.45. In terms of profitability, INBS's ROE is -1.70%, compared to PKI's ROE of +0.03%. Regarding short-term risk, INBS is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for INBS.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
INBS vs CRL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CRL has a market cap of 14B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CRL trades at $295.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CRL's P/E ratio is 29.44. In terms of profitability, INBS's ROE is -1.70%, compared to CRL's ROE of -0.08%. Regarding short-term risk, INBS is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CRL's competition here
Revvity, Inc. (NYSE: RVTY)
INBS vs RVTY Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, RVTY has a market cap of 13.9B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while RVTY trades at $124.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas RVTY's P/E ratio is 23.31. In terms of profitability, INBS's ROE is -1.70%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, INBS is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for INBS.Check RVTY's competition here
ICON Public Limited Company (NASDAQ: ICLR)
INBS vs ICLR Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ICLR trades at $172.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ICLR's P/E ratio is 14.05. In terms of profitability, INBS's ROE is -1.70%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, INBS is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for INBS.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
INBS vs QGEN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, QGEN has a market cap of 9.1B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while QGEN trades at $44.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas QGEN's P/E ratio is 18.22. In terms of profitability, INBS's ROE is -1.70%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, INBS is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for INBS.Check QGEN's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
INBS vs TWST Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, TWST has a market cap of 9.1B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while TWST trades at $145.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas TWST's P/E ratio is -65.58. In terms of profitability, INBS's ROE is -1.70%, compared to TWST's ROE of -0.30%. Regarding short-term risk, INBS is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for INBS.Check TWST's competition here
RadNet, Inc. (NASDAQ: RDNT)
INBS vs RDNT Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while RDNT trades at $76.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas RDNT's P/E ratio is 167.00. In terms of profitability, INBS's ROE is -1.70%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, INBS is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for INBS.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
INBS vs SHC Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, SHC has a market cap of 5.6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while SHC trades at $19.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas SHC's P/E ratio is 20.39. In terms of profitability, INBS's ROE is -1.70%, compared to SHC's ROE of +0.27%. Regarding short-term risk, INBS is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for INBS.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
INBS vs SYNH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas SYNH's P/E ratio is 61.40. In terms of profitability, INBS's ROE is -1.70%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, INBS is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check SYNH's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
INBS vs BLLN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BLLN has a market cap of 4.4B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BLLN trades at $95.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BLLN's P/E ratio is 135.76. In terms of profitability, INBS's ROE is -1.70%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, INBS is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for INBS.Check BLLN's competition here
GRAIL Inc. (NASDAQ: GRAL)
INBS vs GRAL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, GRAL has a market cap of 3.4B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while GRAL trades at $79.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas GRAL's P/E ratio is -8.16. In terms of profitability, INBS's ROE is -1.70%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, INBS is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for INBS.Check GRAL's competition here
Veracyte, Inc. (NASDAQ: VCYT)
INBS vs VCYT Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, VCYT has a market cap of 3.4B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while VCYT trades at $42.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas VCYT's P/E ratio is 21.15. In terms of profitability, INBS's ROE is -1.70%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, INBS is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for INBS.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
INBS vs OLK Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas OLK's P/E ratio is -96.59. In terms of profitability, INBS's ROE is -1.70%, compared to OLK's ROE of -0.07%. Regarding short-term risk, INBS is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for INBS.Check OLK's competition here
Neogen Corporation (NASDAQ: NEOG)
INBS vs NEOG Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NEOG has a market cap of 2.6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NEOG trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NEOG's P/E ratio is 42.68. In terms of profitability, INBS's ROE is -1.70%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, INBS is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for INBS.Check NEOG's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
INBS vs WGS Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while WGS trades at $87.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas WGS's P/E ratio is 241.85. In terms of profitability, INBS's ROE is -1.70%, compared to WGS's ROE of -0.39%. Regarding short-term risk, INBS is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for INBS.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
INBS vs CDNA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CDNA has a market cap of 2.4B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CDNA trades at $48.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CDNA's P/E ratio is 55.94. In terms of profitability, INBS's ROE is -1.70%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, INBS is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
INBS vs PSNL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PSNL has a market cap of 2B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PSNL trades at $18.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PSNL's P/E ratio is -16.86. In terms of profitability, INBS's ROE is -1.70%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, INBS is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for INBS.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
INBS vs OPK Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while OPK trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas OPK's P/E ratio is -5.48. In terms of profitability, INBS's ROE is -1.70%, compared to OPK's ROE of -0.06%. Regarding short-term risk, INBS is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for INBS.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
INBS vs CSTL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CSTL trades at $34.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CSTL's P/E ratio is -74.84. In terms of profitability, INBS's ROE is -1.70%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, INBS is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CSTL's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
INBS vs GRALV Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas GRALV's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to GRALV's ROE of N/A. Regarding short-term risk, INBS is more volatile compared to GRALV. This indicates higher risk in terms of short-term price fluctuations for INBS.Check GRALV's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
INBS vs FLGT Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, FLGT has a market cap of 565.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while FLGT trades at $19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas FLGT's P/E ratio is 1990.00. In terms of profitability, INBS's ROE is -1.70%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, INBS is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for INBS.Check FLGT's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
INBS vs NEO Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NEO has a market cap of 436.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NEO trades at $16.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NEO's P/E ratio is 130.62. In terms of profitability, INBS's ROE is -1.70%, compared to NEO's ROE of -0.06%. Regarding short-term risk, INBS is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for INBS.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
INBS vs CO Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CO's P/E ratio is 5.06. In terms of profitability, INBS's ROE is -1.70%, compared to CO's ROE of +0.11%. Regarding short-term risk, INBS is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for INBS.Check CO's competition here
Prenetics Global Limited (NASDAQ: PRE)
INBS vs PRE Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PRE has a market cap of 343.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PRE trades at $20.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PRE's P/E ratio is -4.99. In terms of profitability, INBS's ROE is -1.70%, compared to PRE's ROE of -0.49%. Regarding short-term risk, INBS is less volatile compared to PRE. This indicates lower risk in terms of short-term price fluctuations for INBS.Check PRE's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
INBS vs MYGN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MYGN has a market cap of 302.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MYGN trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MYGN's P/E ratio is -24.62. In terms of profitability, INBS's ROE is -1.70%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, INBS is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
INBS vs FLDM Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas FLDM's P/E ratio is -4.74. In terms of profitability, INBS's ROE is -1.70%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, INBS is more volatile compared to FLDM. This indicates higher risk in terms of short-term price fluctuations for INBS.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
INBS vs PRENW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PRENW has a market cap of 260.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PRENW's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, INBS is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
INBS vs BDSX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BDSX has a market cap of 216.8M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BDSX trades at $26.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BDSX's P/E ratio is -8.40. In terms of profitability, INBS's ROE is -1.70%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, INBS is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
INBS vs XGN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, XGN has a market cap of 191.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while XGN trades at $7.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas XGN's P/E ratio is -9.78. In terms of profitability, INBS's ROE is -1.70%, compared to XGN's ROE of -1.22%. Regarding short-term risk, INBS is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for INBS.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
INBS vs IMDX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, IMDX has a market cap of 140.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while IMDX trades at $4.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas IMDX's P/E ratio is -2.91. In terms of profitability, INBS's ROE is -1.70%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, INBS is more volatile compared to IMDX. This indicates higher risk in terms of short-term price fluctuations for INBS.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
INBS vs GTH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas GTH's P/E ratio is -1.11. In terms of profitability, INBS's ROE is -1.70%, compared to GTH's ROE of -1.01%. Regarding short-term risk, INBS is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
INBS vs GENE Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas GENE's P/E ratio is -38.25. In terms of profitability, INBS's ROE is -1.70%, compared to GENE's ROE of -1.85%. Regarding short-term risk, INBS is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for INBS.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
INBS vs SERA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, SERA has a market cap of 81.7M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while SERA trades at $2.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas SERA's P/E ratio is -3.29. In terms of profitability, INBS's ROE is -1.70%, compared to SERA's ROE of -0.47%. Regarding short-term risk, INBS is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for INBS.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
INBS vs PRPO Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PRPO has a market cap of 54.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PRPO trades at $30.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PRPO's P/E ratio is -117.12. In terms of profitability, INBS's ROE is -1.70%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, INBS is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for INBS.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
INBS vs MDXH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MDXH has a market cap of 38.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MDXH trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MDXH's P/E ratio is -1.96. In terms of profitability, INBS's ROE is -1.70%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, INBS is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
INBS vs QUCY Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, QUCY has a market cap of 29.6M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while QUCY trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas QUCY's P/E ratio is -0.06. In terms of profitability, INBS's ROE is -1.70%, compared to QUCY's ROE of -3.26%. Regarding short-term risk, INBS is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for INBS.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
INBS vs AKU Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas AKU's P/E ratio is -0.13. In terms of profitability, INBS's ROE is -1.70%, compared to AKU's ROE of -5.32%. Regarding short-term risk, INBS is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for INBS.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
INBS vs CEMI Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CEMI's P/E ratio is -0.63. In terms of profitability, INBS's ROE is -1.70%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, INBS is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
INBS vs ENZ Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ENZ's P/E ratio is -2.24. In terms of profitability, INBS's ROE is -1.70%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, INBS is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for INBS.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
INBS vs PMD Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PMD's P/E ratio is -5.24. In terms of profitability, INBS's ROE is -1.70%, compared to PMD's ROE of -0.32%. Regarding short-term risk, INBS is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for INBS.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
INBS vs ME Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ME's P/E ratio is -0.03. In terms of profitability, INBS's ROE is -1.70%, compared to ME's ROE of -42.03%. Regarding short-term risk, INBS is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for INBS.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
INBS vs MYNZ Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, INBS's ROE is -1.70%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, INBS is more volatile compared to MYNZ. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MYNZ's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
INBS vs ADVB Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ADVB has a market cap of 11.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ADVB trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ADVB's P/E ratio is -74.00. In terms of profitability, INBS's ROE is -1.70%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, INBS is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for INBS.Check ADVB's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
INBS vs BNR Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BNR has a market cap of 11.2M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BNR trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BNR's P/E ratio is -12.87. In terms of profitability, INBS's ROE is -1.70%, compared to BNR's ROE of -0.11%. Regarding short-term risk, INBS is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
INBS vs CHEK Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CHEK's P/E ratio is -0.43. In terms of profitability, INBS's ROE is -1.70%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, INBS is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
INBS vs CNTG Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CNTG's P/E ratio is -0.23. In terms of profitability, INBS's ROE is -1.70%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, INBS is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for INBS.Check CNTG's competition here
Check-Cap Ltd. Ordinary Share (NASDAQ: MBAI)
INBS vs MBAI Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MBAI has a market cap of 8.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MBAI trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MBAI's P/E ratio is 12.07. In terms of profitability, INBS's ROE is -1.70%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, INBS is more volatile compared to MBAI. This indicates higher risk in terms of short-term price fluctuations for INBS.Check MBAI's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
INBS vs APDN Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas APDN's P/E ratio is -0.10. In terms of profitability, INBS's ROE is -1.70%, compared to APDN's ROE of -7.23%. Regarding short-term risk, INBS is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for INBS.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
INBS vs NDRA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NDRA has a market cap of 5.7M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NDRA trades at $4.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NDRA's P/E ratio is -0.57. In terms of profitability, INBS's ROE is -1.70%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, INBS is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for INBS.Check NDRA's competition here
Invitae Corporation (NYSE: NVTA)
INBS vs NVTA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NVTA's P/E ratio is -0.00. In terms of profitability, INBS's ROE is -1.70%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, INBS is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for INBS.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
INBS vs LMDXW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, INBS's ROE is -1.70%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, INBS is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
INBS vs LMDX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas LMDX's P/E ratio is -0.01. In terms of profitability, INBS's ROE is -1.70%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, INBS is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for INBS.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
INBS vs BIAFW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BIAFW has a market cap of 4.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BIAFW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BIAFW's P/E ratio is 0.44. In terms of profitability, INBS's ROE is -1.70%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, INBS is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
INBS vs DMTK Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas DMTK's P/E ratio is -0.04. In terms of profitability, INBS's ROE is -1.70%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, INBS is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for INBS.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
INBS vs NOTV Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NOTV's P/E ratio is -0.03. In terms of profitability, INBS's ROE is -1.70%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, INBS is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for INBS.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
INBS vs SQL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas SQL's P/E ratio is -0.40. In terms of profitability, INBS's ROE is -1.70%, compared to SQL's ROE of -30.46%. Regarding short-term risk, INBS is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for INBS.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
INBS vs AWH Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas AWH's P/E ratio is -0.09. In terms of profitability, INBS's ROE is -1.70%, compared to AWH's ROE of +1.62%. Regarding short-term risk, INBS is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for INBS.Check AWH's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
INBS vs BIAF Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BIAF has a market cap of 2.4M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BIAF trades at $0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BIAF's P/E ratio is -0.05. In terms of profitability, INBS's ROE is -1.70%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, INBS is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BIAF's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
INBS vs HTGM Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas HTGM's P/E ratio is -0.03. In terms of profitability, INBS's ROE is -1.70%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, INBS is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for INBS.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
INBS vs BIOC Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BIOC's P/E ratio is -0.01. In terms of profitability, INBS's ROE is -1.70%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, INBS is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
INBS vs ISPC Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, ISPC has a market cap of 231.9K. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while ISPC trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas ISPC's P/E ratio is -0.05. In terms of profitability, INBS's ROE is -1.70%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, INBS is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for INBS.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
INBS vs SQLLW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, INBS's ROE is -1.70%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, INBS is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
INBS vs WGSWW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, INBS's ROE is -1.70%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, INBS is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for INBS.Check WGSWW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
INBS vs CHEKZ Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, INBS is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for INBS.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
INBS vs OCDX Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas OCDX's P/E ratio is -42.28. In terms of profitability, INBS's ROE is -1.70%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, INBS is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for INBS.Check OCDX's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
INBS vs NDRAW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas NDRAW's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, INBS is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
INBS vs DHR-PA Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, INBS's ROE is -1.70%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, INBS is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for INBS.Check DHR-PA's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
INBS vs BNGOW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas BNGOW's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, INBS is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check BNGOW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
INBS vs PRXL Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas PRXL's P/E ratio is 42.97. In terms of profitability, INBS's ROE is -1.70%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, INBS is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for INBS.Check PRXL's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
INBS vs MEUSW Comparison August 2026
Intelligent Bio Solutions Inc. (NASDAQ: INBS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INBS stands at 1.6M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, INBS is priced at $2.51 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INBS currently has a P/E ratio of -0.28, whereas MEUSW's P/E ratio is N/A. In terms of profitability, INBS's ROE is -1.70%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, INBS is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for INBS.Check MEUSW's competition here